靶向肠道微生物群的治疗对帕金森病运动和非运动症状的比较疗效:一项系统综述和网络荟萃分析。
完整摘要 · 中文译文
背景:肠道菌群失调可能通过微生物群-肠-脑轴促进帕金森病(PD)的发生。益生菌、合生元和粪菌移植(FMT)已被研究作为潜在治疗方法,但其比较效应仍不确定。 方法:我们检索了从建库至2026年4月1日的试验注册库和电子数据库,纳入针对PD肠道菌群靶向治疗的随机对照试验。我们进行了频率学派网状荟萃分析。采用Cochrane RoB 2评估偏倚风险,采用CINeMA评估证据确定性。治疗排名采用SUCRA值进行总结。 结果:共纳入19项随机对照试验,涉及1,156名参与者和五种治疗方案(FMT、益生菌、合生元、常规护理和安慰剂)。与安慰剂相比,益生菌增加了自发性排便(SBM)频率(MD = 1.93,95% CI:0.23至3.64;SUCRA = 88.3%)。在口服给药亚组中,益生菌(MD = 2.01,95% CI:0.64至3.39)和合生元(MD = 1.23,95% CI:0.01至2.45)增加了SBM频率。与安慰剂相比,无活性治疗显著改善MDS-UPDRS III评分,尽管合生元和FMT的SUCRA排名较高。口服益生菌对SBM频率的证据确定性为中等,对运动功能和生活质量的证据确定性为低至极低。 结论:口服益生菌改善了PD患者的SBM频率。运动功能和生活质量的证据不确定,FMT和合生元的较高排名应视为探索性。更大规模的头对头随机 需要随机对照试验。 系统综述注册:https://www.crd.york.ac.uk/PROSPERO/recorddashboard。
完整摘要 · 英文原文
BACKGROUND: Gut dysbiosis may contribute to Parkinson's disease (PD) through the microbiota-gut-brain axis. Probiotics, synbiotics, and fecal microbiota transplantation (FMT) have been studied as potential treatments, but their comparative effects remain uncertain. METHODS: We searched trial registries and electronic databases from inception to April 1, 2026 for randomized controlled trials of gut microbiota-targeted therapies in PD. We performed a frequentist network meta-analysis. Risk of bias was assessed with Cochrane RoB 2, and confidence in the evidence was assessed with CINeMA. Treatment rankings were summarized using SUCRA values. RESULTS: Nineteen RCTs involving 1,156 participants and five treatment options (FMT, probiotics, synbiotics, routine care, and placebo) were included. Probiotics increased spontaneous bowel movement (SBM) frequency compared with placebo (MD = 1.93, 95% CI: 0.23 to 3.64; SUCRA = 88.3%). In the oral-administration subgroup, probiotics (MD = 2.01, 95% CI: 0.64 to 3.39) and synbiotics (MD = 1.23, 95% CI: 0.01 to 2.45) increased SBM frequency. No active treatment significantly improved MDS-UPDRS III scores compared with placebo, although synbiotics and FMT had higher SUCRA rankings. Evidence certainty was Moderate for oral probiotics on SBM frequency and Low to Very Low for motor function and quality of life. CONCLUSION: Oral probiotics improved SBM frequency in patients with PD. Evidence for motor function and quality of life was uncertain, and the higher rankings of FMT and synbiotics should be considered exploratory. Larger head-to-head randomized trials are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/recorddashboard.